Sep. 20 at 1:58 AM
$CANF is one of the most under the radar biotech plays in the market with the potential to become a massive multi-bagger. Trading near all-time lows, the company holds a deep pipeline led by Piclidenoson and Namodenoson two clinical-stage drug candidates targeting blockbuster markets like psoriasis, liver cancer, MASH, and pancreatic cancer. With over
$685 million in projected future partnership revenues, multiple regulatory designations including orphan and fast track status, and a growing list of international collaborations, CANF is positioning itself for a breakout. If even one of its late-stage trials succeeds, the re rating could be explosive. Given its tiny market cap and low float, the upside per share is enormous and some models even suggest an intrinsic value as high as
$600+ based on long term projections and market penetration. For risk-tolerant investors, this is the kind of asymmetrical biotech setup that can go from penny stock to powerhouse
$XBI $QLGN $BLNE ..
